• Something wrong with this record ?

Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer

M. Gómez-Herranz, J. Faktor, M. Yébenes Mayordomo, M. Pilch, M. Nekulova, L. Hernychova, KL. Ball, B. Vojtesek, TR. Hupp, S. Kote

. 2022 ; 12 (8) : . [pub] 20220808

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
BB/C511599/1 Biotechnology and Biological Sciences Research Council - United Kingdom

The IFITM restriction factors play a role in cancer cell progression through undefined mechanisms. We investigate new protein-protein interactions for IFITM1/3 in the context of cancer that would shed some light on how IFITM1/3 attenuate the expression of targeted proteins such as HLA-B. SBP-tagged IFITM1 protein was used to identify an association of IFITM1 protein with the SRSF1 splicing factor and transporter of mRNA to the ribosome. Using in situ proximity ligation assays, we confirmed a predominant cytosolic protein-protein association for SRSF1 and IFITM1/3. Accordingly, IFITM1/3 interacted with HLA-B mRNA in response to IFNγ stimulation using RNA-protein proximity ligation assays. In addition, RT-qPCR assays in IFITM1/IFITM3 null cells and wt-SiHa cells indicated that HLA-B gene expression at the mRNA level does not account for lowered HLA-B protein synthesis in response to IFNγ. Complementary, shotgun RNA sequencing did not show major transcript differences between IFITM1/IFITM3 null cells and wt-SiHa cells. Furthermore, ribosome profiling using sucrose gradient sedimentation identified a reduction in 80S ribosomal fraction an IFITM1/IFITM3 null cells compared to wild type. It was partially reverted by IFITM1/3 complementation. Our data link IFITM1/3 proteins to HLA-B mRNA and SRSF1 and, all together, our results begin to elucidate how IFITM1/3 catalyze the synthesis of target proteins. IFITMs are widely studied for their role in inhibiting viruses, and multiple studies have associated IFITMs with cancer progression. Our study has identified new proteins associated with IFITMs which support their role in mediating protein expression; a pivotal function that is highly relevant for viral infection and cancer progression. Our results suggest that IFITM1/3 affect the expression of targeted proteins; among them, we identified HLA-B. Changes in HLA-B expression could impact the presentation and recognition of oncogenic antigens on the cell surface by cytotoxic T cells and, ultimately, limit tumor cell eradication. In addition, the role of IFITMs in mediating protein abundance is relevant, as it has the potential for regulating the expression of viral and oncogenic proteins.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024886
003      
CZ-PrNML
005      
20221031100602.0
007      
ta
008      
221017s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biom12081090 $2 doi
035    __
$a (PubMed)36008984
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gómez-Herranz, Maria $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $1 https://orcid.org/000000020403609X
245    10
$a Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer / $c M. Gómez-Herranz, J. Faktor, M. Yébenes Mayordomo, M. Pilch, M. Nekulova, L. Hernychova, KL. Ball, B. Vojtesek, TR. Hupp, S. Kote
520    9_
$a The IFITM restriction factors play a role in cancer cell progression through undefined mechanisms. We investigate new protein-protein interactions for IFITM1/3 in the context of cancer that would shed some light on how IFITM1/3 attenuate the expression of targeted proteins such as HLA-B. SBP-tagged IFITM1 protein was used to identify an association of IFITM1 protein with the SRSF1 splicing factor and transporter of mRNA to the ribosome. Using in situ proximity ligation assays, we confirmed a predominant cytosolic protein-protein association for SRSF1 and IFITM1/3. Accordingly, IFITM1/3 interacted with HLA-B mRNA in response to IFNγ stimulation using RNA-protein proximity ligation assays. In addition, RT-qPCR assays in IFITM1/IFITM3 null cells and wt-SiHa cells indicated that HLA-B gene expression at the mRNA level does not account for lowered HLA-B protein synthesis in response to IFNγ. Complementary, shotgun RNA sequencing did not show major transcript differences between IFITM1/IFITM3 null cells and wt-SiHa cells. Furthermore, ribosome profiling using sucrose gradient sedimentation identified a reduction in 80S ribosomal fraction an IFITM1/IFITM3 null cells compared to wild type. It was partially reverted by IFITM1/3 complementation. Our data link IFITM1/3 proteins to HLA-B mRNA and SRSF1 and, all together, our results begin to elucidate how IFITM1/3 catalyze the synthesis of target proteins. IFITMs are widely studied for their role in inhibiting viruses, and multiple studies have associated IFITMs with cancer progression. Our study has identified new proteins associated with IFITMs which support their role in mediating protein expression; a pivotal function that is highly relevant for viral infection and cancer progression. Our results suggest that IFITM1/3 affect the expression of targeted proteins; among them, we identified HLA-B. Changes in HLA-B expression could impact the presentation and recognition of oncogenic antigens on the cell surface by cytotoxic T cells and, ultimately, limit tumor cell eradication. In addition, the role of IFITMs in mediating protein abundance is relevant, as it has the potential for regulating the expression of viral and oncogenic proteins.
650    _2
$a diferenciační antigeny $x metabolismus $7 D000943
650    _2
$a ženské pohlaví $7 D005260
650    12
$a HLA-B antigeny $x metabolismus $7 D015235
650    _2
$a lidé $7 D006801
650    _2
$a membránové proteiny $x genetika $x metabolismus $7 D008565
650    _2
$a sestřihové faktory $7 D000072260
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a proteiny vázající RNA $x genetika $x metabolismus $7 D016601
650    _2
$a serin-arginin sestřihové faktory $x genetika $7 D000068103
650    12
$a nádory děložního čípku $x genetika $7 D002583
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Faktor, Jakub $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic
700    1_
$a Yébenes Mayordomo, Marcos $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $1 https://orcid.org/0000000156738440
700    1_
$a Pilch, Magdalena $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland
700    1_
$a Nekulova, Marta $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000164042566
700    1_
$a Hernychova, Lenka $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic
700    1_
$a Ball, Kathryn L $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK
700    1_
$a Vojtesek, Borivoj $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000161943705
700    1_
$a Hupp, Ted R $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland $u Masaryk Memorial Cancer Institute, Research Centre for Applied Molecular Oncology, 65653 Brno, Czech Republic $1 https://orcid.org/0000000303910352
700    1_
$a Kote, Sachin $u International Centre for Cancer Vaccine Science, University of Gdańsk, 80-822 Gdańsk, Poland
773    0_
$w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 12, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36008984 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100600 $b ABA008
999    __
$a ok $b bmc $g 1854543 $s 1176176
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 8 $e 20220808 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
GRA    __
$a BB/C511599/1 $p Biotechnology and Biological Sciences Research Council $2 United Kingdom
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...